Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBIT Margin (2020 - 2026)

GeneDx Holdings has reported EBIT Margin over the past 7 years, most recently at 56.2% for Q1 2026.

  • Quarterly EBIT Margin fell 5098.0% to 56.2% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 14.91% through Mar 2026, down 1064.0% year-over-year, with the annual reading at 3.06% for FY2025, 454.0% up from the prior year.
  • EBIT Margin was 56.2% for Q1 2026 at GeneDx Holdings, down from 11.77% in the prior quarter.
  • Over five years, EBIT Margin peaked at 9.21% in Q4 2024 and troughed at 529.56% in Q4 2022.
  • The 5-year median for EBIT Margin is 44.66% (2023), against an average of 101.77%.
  • Year-over-year, EBIT Margin plummeted -35302bps in 2022 and then surged 48489bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 529.56% in 2022, then soared by 92bps to 44.66% in 2023, then surged by 121bps to 9.21% in 2024, then plummeted by -228bps to 11.77% in 2025, then plummeted by -378bps to 56.2% in 2026.
  • Per Business Quant, the three most recent readings for WGS's EBIT Margin are 56.2% (Q1 2026), 11.77% (Q4 2025), and 2.78% (Q3 2025).